DK3215530T3 - Forbedrede il-6 antistoffer - Google Patents

Forbedrede il-6 antistoffer Download PDF

Info

Publication number
DK3215530T3
DK3215530T3 DK15797538T DK15797538T DK3215530T3 DK 3215530 T3 DK3215530 T3 DK 3215530T3 DK 15797538 T DK15797538 T DK 15797538T DK 15797538 T DK15797538 T DK 15797538T DK 3215530 T3 DK3215530 T3 DK 3215530T3
Authority
DK
Denmark
Prior art keywords
antibodies
improved
Prior art date
Application number
DK15797538T
Other languages
English (en)
Inventor
Alison Tisdale
Eric Steven Furfine
Grigorios Zarbis-Papastoitsis
Michael March Schmidt
Original Assignee
Sesen Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sesen Bio Inc filed Critical Sesen Bio Inc
Application granted granted Critical
Publication of DK3215530T3 publication Critical patent/DK3215530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15797538T 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer DK3215530T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28
PCT/US2015/059532 WO2016073890A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (1)

Publication Number Publication Date
DK3215530T3 true DK3215530T3 (da) 2019-11-25

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15797538T DK3215530T3 (da) 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer

Country Status (32)

Country Link
US (2) US11142571B2 (da)
EP (3) EP3215530B9 (da)
JP (1) JP6594438B2 (da)
KR (2) KR20240023450A (da)
CN (1) CN107249631B (da)
AU (1) AU2015342882B2 (da)
BR (1) BR112017008672A2 (da)
CA (1) CA2965689C (da)
CL (1) CL2017001135A1 (da)
CO (1) CO2017005404A2 (da)
CR (1) CR20170231A (da)
DK (1) DK3215530T3 (da)
EA (1) EA035199B1 (da)
ES (1) ES2756275T3 (da)
HK (1) HK1244008A1 (da)
HR (1) HRP20191945T1 (da)
HU (1) HUE046181T2 (da)
IL (1) IL251858B (da)
MA (1) MA51554A (da)
MX (2) MX2017005992A (da)
MY (1) MY185114A (da)
PE (1) PE20171107A1 (da)
PH (1) PH12017500809A1 (da)
PL (1) PL3215530T3 (da)
PT (1) PT3215530T (da)
RS (1) RS59805B1 (da)
SA (1) SA517381458B1 (da)
SG (2) SG11201703574VA (da)
SI (1) SI3215530T1 (da)
UA (1) UA122673C2 (da)
WO (1) WO2016073890A1 (da)
ZA (1) ZA201702985B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
BR112018017031A2 (pt) * 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
IL269506B2 (en) 2017-03-22 2024-04-01 Genentech Inc Hyaluronic acid cross-linked hydrogel preparations and methods
KR20190138636A (ko) 2017-03-22 2019-12-13 제넨테크, 인크. 안구 장애의 치료를 위한 최적화된 항체 조성물
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
BR112022018254A2 (pt) 2020-03-13 2022-10-25 Genentech Inc Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
EP4228702A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
TW202426494A (zh) * 2022-10-24 2024-07-01 瑞士商赫孚孟拉羅股份公司 預測對ｉｌ－６拮抗劑的反應

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (da) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
AU2002363339B2 (en) 2001-11-08 2008-02-07 Abbvie Biotechnology Ltd Stable liquid pharmaceutical formulation of IGG antibodies
EP1503731A1 (en) 2002-05-07 2005-02-09 Control Delivery Systems, Inc. Processes for forming a drug delivery device
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
EP2402756A3 (en) 2003-12-23 2012-02-22 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
JP5055603B2 (ja) 2004-08-04 2012-10-24 メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー 変異Ｆｃ領域
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0620797A2 (pt) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschonkter Haftung anticorpos anti-il-6 que previnem a ligação de il-6 complexado com il-6ralfa a gp130
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20070269868A1 (en) 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
BRPI0811782A2 (pt) * 2007-05-21 2019-02-26 Alder Biopharmaceuticals, Inc. anticorpos para il-6 e uso dos mesmos
PT2198007T (pt) 2007-09-14 2018-01-29 Sanofi Pasteur Biologics Llc Composições farmacêuticas contendo toxoides a e b de clostridium difficile
CN101925611A (zh) 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
AR072897A1 (es) 2008-08-05 2010-09-29 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP5033921B2 (ja) 2008-09-12 2012-09-26 株式会社ケーディエフ 噴水装置
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
MX2011005540A (es) 2008-11-26 2011-06-21 Glaxo Group Ltd Polipeptidos dominios variables de anticuerpos, y antagonistas.
AU2010208125B2 (en) 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
SG11201502659YA (en) 2012-10-25 2015-05-28 Medimmune Llc Stable, low viscosity antibody formulation
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
EP3628373A1 (en) 2013-07-12 2020-04-01 IVERIC bio, Inc. Methods for treating or preventing opthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
WO2016073890A1 (en) 2016-05-12
BR112017008672A2 (pt) 2018-03-20
KR20170077196A (ko) 2017-07-05
UA122673C2 (uk) 2020-12-28
EP4268843A2 (en) 2023-11-01
CN107249631A (zh) 2017-10-13
JP2017535285A (ja) 2017-11-30
US20190194312A1 (en) 2019-06-27
NZ731090A (en) 2024-03-22
MX2021008663A (es) 2021-08-19
CA2965689A1 (en) 2016-05-12
JP6594438B2 (ja) 2019-10-23
US20220169719A1 (en) 2022-06-02
HUE046181T2 (hu) 2020-02-28
EA035199B1 (ru) 2020-05-14
PT3215530T (pt) 2019-11-21
EA201791005A1 (ru) 2017-09-29
US11142571B2 (en) 2021-10-12
MX2017005992A (es) 2017-09-15
PE20171107A1 (es) 2017-08-07
SI3215530T1 (sl) 2020-02-28
AU2015342882B2 (en) 2021-05-20
IL251858A0 (en) 2017-06-29
KR102636726B1 (ko) 2024-02-13
CA2965689C (en) 2022-03-22
HRP20191945T1 (hr) 2020-01-24
CR20170231A (es) 2017-09-25
PH12017500809A1 (en) 2017-10-02
SA517381458B1 (ar) 2020-07-09
RS59805B1 (sr) 2020-02-28
SG10202103420PA (en) 2021-05-28
SG11201703574VA (en) 2017-05-30
ES2756275T9 (es) 2020-10-29
EP3215530A1 (en) 2017-09-13
EP3215530B1 (en) 2019-08-21
AU2015342882A1 (en) 2017-05-18
CN107249631B (zh) 2021-11-23
CO2017005404A2 (es) 2017-10-31
MY185114A (en) 2021-04-30
EP3632931A1 (en) 2020-04-08
KR20240023450A (ko) 2024-02-21
CL2017001135A1 (es) 2017-12-15
IL251858B (en) 2022-09-01
ZA201702985B (en) 2019-10-30
EP3215530B9 (en) 2020-09-09
HK1244008A1 (zh) 2018-07-27
MA51554A (fr) 2020-11-18
EP4268843A3 (en) 2023-12-27
ES2756275T3 (es) 2020-04-27
PL3215530T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
DK3344654T3 (da) Anti-lag-3-antistoffer
KR102355950B9 (ko) Tigit에 대한 항체
DK3126395T3 (da) Multispecifikke antistoffer
DK3556777T3 (da) Multispecifikke antistofkonstrukter
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3157559T3 (da) Anti-axl-antistoffer
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
HK1244008A1 (zh) 改進的il-6抗體
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3099791T3 (da) Protein
DK3484921T3 (da) Anti-IL-22R antistoffer
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3126391T3 (da) ANTISTOFFER MOD HPA-1a
DK3099793T3 (da) Protein
FI20145330A (fi) Immunomääritys
BR112017002234A2 (pt) anticorpos anti-pd-l1
UA30337S (uk) Карбюратор
UA30336S (uk) Карбюратор
UA30317S (uk) Карбюратор
UA30329S (uk) Карбюратор
DE112015004618A5 (de) Garnitur